Business
Currency:USD
2024/FY
Stock NameRevenueRatio
Discovery and development of therapies utilizing our novel proprietary ARCUS platform68.7M100.00%
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States68.7M100.00%